Market News & Trends
Exostar Launches Cybersecurity Risk Assessment Solution
Exostar, whose cloud-based solutions help companies in aerospace and defense, life sciences, and healthcare mitigate risk and solve their identity and access challenges, recently announced…
Celldex Therapeutics Initiates Phase I/II Study
Celldex Therapeutics, Inc. recently announced the initiation of an open-label, Phase I/II safety and tolerability study examining the investigational combination of varlilumab and Roche's atezolizumab…
Pharmaceutical Deals Crucial to Offsetting $2.5-Billion Cost of Developing a Novel Drug
With the average cost of getting a novel drug to market at almost $2.5 billion, and few products achieving blockbuster status, deal-making is becoming increasingly…
Soligenix Announces Initiation of Pivotal Phase III Clinical Trial
Soligenix, Inc. recently announced that patient enrollment has been opened for its Phase III, multicenter, randomized, double-blind, placebo-controlled study evaluating SGX301 (synthetic hypericin), as a…
Pharma Outsourcing M&As Set for Record Year in 2015
A drastic increase in Mergers and Acquisitions (M&A) activity propelled the value of pharmaceutical outsourcing deals from $9.9 billion in 2014 to nearly $17.6 billion…
Ajinomoto Althea Launches Process & Analytical Development Services for ADC Therapeutics
Ajinomoto Althea, Inc., a leading provider of biopharmaceutical contract development and manufacturing services, recently announced it is expanding its existing biological drug product manufacturing operations…
Global Immunology Treatment Market Will Exceed $74 Billion by 2022
Despite the imminent patent expiry of many therapies, the global immunology treatment market is set to expand, from $61.5 billion in 2015 to reach $74.2…
Caladrius Biosciences Announces Two-Year Study Results
Caladrius Biosciences, Inc. recently announced the publication of 2-year results from a Phase I clinical study of an autologous Regulatory T cell (Treg) immunotherapy for…
BioCellChallenge Obtains Unprecedented In Vivo Results
BioCellChallenge SAS recently announced its positive results from in-vivo tests of a therapeutic antibody. The results confirm the efficacy of BioCellChallenge’s ImmunoCellin technology, which allows…
Adaptimmune & Universal Cells Announce Collaboration & License Agreement
Adaptimmune Therapeutics plc and Universal Cells Inc. recently announced they have entered into a collaboration and exclusive license agreement for the development of allogeneic T-cell…
Ashland Aids Pharmaceutical Manufacturers With Formulation Services
Pharmaceutical scientists at Ashland understand how polymers interact with complex drug molecules. These experts presented at CPhI India to explain how Ashland is providing formulation…
Vetter Receives Internationally Recognized AEO-F Certificate
Vetter has received the status of Authorized Economic Operator Full (AEO-F) from the European Union confirming Vetter reliability, solvency, and high safety standards in international…
ProQR Announces R&D Day; Provides Update on Innovation Portfolio
ProQR Therapeutics N.V. recently announced an update on the innovation pipeline and an R&D day for investors. ProQR has been investing in its Innovation Platform…
Aptar Pharma Presents a Step Change in the Performance of DF30Plus for PMDIs Incorporating COC
Aptar Pharma, a global solution provider of innovative and proven aerosol, injection, and spray delivery systems for biotech, healthcare, and pharma products, will present its…
SteadyMed Demonstrates Potential for Reduced Infusion Site Sensitivity Associated With Trevyent Compared to Remodulin
SteadyMed Ltd., a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value diseases with unmet parenteral delivery needs, recently…
Strongbridge Biopharma Announces Issuance of US Patent for Investigational COR-003 in Treatment of Endogenous Cushing's Syndrome
Strongbridge Biopharma plc recently announced that the United States Patent and Trademark Office (USPTO) issued a patent related to the Company's lead investigational drug candidate,…
Pfizer Awards Flagship OTC Product Manufacturing Contract to Catalent
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, consumer health and animal health products, recently announced…
New Phase III Data Show Optune in Combination With Second-Line Chemotherapy is Superior
Novocure recently announced new Phase III data showing that glioblastoma patients who received TTFields in combination with chemotherapy at first recurrence lived significantly longer than…
LSP & Bristol-Myers Squibb Enter Strategic Collaboration for Life Sciences Innovation
LSP (Life Sciences Partners) recently announced a strategic collaboration with Bristol-Myers Squibb Company in which the companies will work closely together in identifying European breakthrough…
Novozymes Half-Life Extension Technology Embraced by Paras Biopharmaceuticals to Develop New Biobetter
Novozymes Biopharma and Paras Biopharmaceuticals will collaborate to generate an improved version (a biobetter) of Teriparatide, a leading treatment for osteoporosis, a debilitating bone disease…